AR110351A1 - COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa - Google Patents
COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNaInfo
- Publication number
- AR110351A1 AR110351A1 ARP170103473A ARP170103473A AR110351A1 AR 110351 A1 AR110351 A1 AR 110351A1 AR P170103473 A ARP170103473 A AR P170103473A AR P170103473 A ARP170103473 A AR P170103473A AR 110351 A1 AR110351 A1 AR 110351A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ifna
- heteroarilo
- phosphinoxide
- rented
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003004 phosphinoxides Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 230000011234 negative regulation of signal transduction Effects 0.000 abstract 1
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical group [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos o un estereoisómero o una sal de aquellos aceptable desde el punto de vista farmacéutico, útiles para la modulación de IL-12, IL-23 y/o IFNa que actúan en Tyk-2 para generar la inhibición de la transducción de señal. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde: X es -N- o -CH-; Y es -N- o -CH-; R¹ es CD₃, C₁₋₃ alquilo o C₃₋₆ cicloalquilo; R² es CO-C₃₋₆ cicloalquilo, C₅₋₈ arilo o un heterociclilo de 5 - 7 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, sustituidos con 0 - 4 R²ᵃ; R²ᵃ es, independientemente de cada caso, hidrógeno, halógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, C₅₋₈ arilo o un heterociclilo de 5 - 7 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, en donde dicho arilo o heterociclilo se sustituye con 0 - 2 Rᵃ; Rᵃ es hidrógeno, halógeno o C₁₋₄ alquilo; R³ es P(O)-(C₁₋₄ alquilo)₂; o un estereoisómero o una sal de aquel aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110351A1 true AR110351A1 (es) | 2019-03-20 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103473A AR110351A1 (es) | 2016-12-13 | 2017-12-12 | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (es) |
| EP (1) | EP3555111B1 (es) |
| JP (1) | JP7046092B2 (es) |
| KR (1) | KR102602558B1 (es) |
| CN (1) | CN110267964B (es) |
| AR (1) | AR110351A1 (es) |
| ES (1) | ES2907008T3 (es) |
| MA (1) | MA48602A (es) |
| TW (1) | TW201827423A (es) |
| WO (1) | WO2018111787A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202004592TA (en) | 2017-11-21 | 2020-06-29 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| WO2019178079A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| ES2944733T3 (es) * | 2018-03-22 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013958A1 (en) | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
| WO2009143389A1 (en) * | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| US9060515B2 (en) * | 2011-12-21 | 2015-06-23 | Biota Europe Ltd. | Heterocyclic urea compounds |
| WO2013169401A1 (en) * | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| ES2702148T3 (es) * | 2012-11-08 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa |
| BR112015010244A8 (pt) | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
-
2017
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en unknown
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR102602558B1 (ko) | 2023-11-14 |
| CN110267964B (zh) | 2022-05-03 |
| JP7046092B2 (ja) | 2022-04-01 |
| EP3555111A1 (en) | 2019-10-23 |
| WO2018111787A1 (en) | 2018-06-21 |
| MA48602A (fr) | 2020-03-18 |
| ES2907008T3 (es) | 2022-04-21 |
| KR20190091536A (ko) | 2019-08-06 |
| US10294256B2 (en) | 2019-05-21 |
| JP2020502268A (ja) | 2020-01-23 |
| CN110267964A (zh) | 2019-09-20 |
| TW201827423A (zh) | 2018-08-01 |
| EP3555111B1 (en) | 2022-01-26 |
| US20180162889A1 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110351A1 (es) | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
| AR119761A2 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| DK3774791T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
| EA201591491A1 (ru) | Соединения тетрагидропирролотиазина | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201790922A1 (ru) | Ингибиторы бромодомена | |
| EA201790328A1 (ru) | Диоксолановые аналоги уридина для лечения рака | |
| AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| CO2020006139A2 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
| CY1122563T1 (el) | ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
| EA201891562A2 (ru) | ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt | |
| EA201790343A1 (ru) | Способ получения сульфамидных производных пиримидина | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| AR098037A1 (es) | Derivados de piperazina y su uso como medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |